Trillium's biologics are designed to help the immune system of patients identify and destroy cancer cells, Pfizer said. Its two lead candidates include the signal-regulatory protein alpha fragment crystallizable region (SIRPα-Fc) fusion proteins TTI-622 and TTI-621, which block the key immune checkpoint SIRPα-CD47 axis. The molecules are currently in phase IB/II development.

The move comes almost a year after Pfizer invested $25 million in Trillium as part of its Pfizer Breakthrough Growth Initiative, which offers scientific research funding and access to Pfizer's experts, it said.

FDA authorizes 3rd COVID vaccine dose for immunocompromised individuals
The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines.

Africa to get doses of Pfizer-BioNTech COVID-19 vaccine
Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine...

AbbVie, Biogen, Pfizer release protein-coding genetic variants resource
A collaboration between AbbVie, Biogen, and Pfizer has created and recently launched a browsable resource that links rare protein-coding genetic variants...

Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults
Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19...

Pfizer invests $120M in biotech innovation
Pfizer has invested $120 million in four clinical-stage biotech companies as part of its Pfizer Breakthrough Growth Initiative.